Các lựa chọn điều trị cho ung thư tinh hoàn ở giai đoạn I và II với sự cân nhắc về độc tính lâu dài

Albers P, Hiester A, Grosse Siemer R, Lusch A (2019) The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment. J Clin Oncol 37(7_suppl):507. https://doi.org/10.1200/JCO.2019.37.7_suppl.507

Second Spanish Germ Cell Cancer Cooperative Group, Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A et al (2005) Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23(34):8717–8723. https://doi.org/10.1200/JCO.2005.01.9810

Aparicio J, Maroto P, del Muro XG, Guma J, Sanchez-Munoz A, Margeli M, Germa JR et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29(35):4677–4681. https://doi.org/10.1200/JCO.2011.36.0503

Bamberg M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Flink M et al (1999) Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 83(6):823–827

Chovanec M, Zaid AM, Hanna N, El-Kouri N, Einhorn LH, Albany C (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 28(11):2670–2679. https://doi.org/10.1093/annonc/mdx360

Chung PWM, Gospodarowicz MK, Panzarella T, Jewett MAS, Sturgeon JFG, Tew-George B, Warde PR et al (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45(6):754–759. https://doi.org/10.1016/j.eururo.2004.01.020 (discussion 759-60)

Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Bamberg M et al (2003) Radiotherapy for stages IIA/B testicular seminoma: Final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106. https://doi.org/10.1200/JCO.2003.06.065

Dieckmann K‑P, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Pichlmeier U et al (2016) Seminoma Clinical Stage 1—Patterns of Care in Germany. Urol Int 96(4):390–398. https://doi.org/10.1159/000443214

Fehr M, Maranta AF, Reichegger H, Gillessen S, Cathomas R (2018) Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage i. ESMO Open 3(3):1–5. https://doi.org/10.1136/esmoopen-2018-000320

Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, Brea ML, Arranz JA, Germá-Lluch JR et al (2008) Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish germ cell cancer group study. J Clin Oncol 26(33):5416–5421. https://doi.org/10.1200/JCO.2007.15.9103

Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, Necchi A et al (2015) Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 26(4):657–668. https://doi.org/10.1093/annonc/mdu447

Glaser SM, Vargo JA, Balasubramani GK, Beriwal S (2016) Stage II testicular seminoma: patterns of care and survival by treatment strategy. Clin Oncol 28(8):513–521. https://doi.org/10.1016/j.clon.2016.02.008

Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R, & Interdisziplinäre Arbeitsgruppe Hodentumore (2011) Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations. Urologe A 50(7):830–835. https://doi.org/10.1007/s00120-011-2556-0

Haugnes HS, Oldenburg J, Bremnes RM (2015) Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol Semin Orig Investig 33(9):399–406. https://doi.org/10.1016/j.urolonc.2014.11.012

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Horwich A et al (2018) ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 29(8):1658–1686. https://doi.org/10.1093/annonc/mdy217

Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Hall E et al (2014) Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110(1):256–263. https://doi.org/10.1038/bjc.2013.551

Interdisziplinäre Arbeitsgruppe Hodentumore, Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F et al (2011) Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 34(1–2):59–64. https://doi.org/10.1159/000323346

Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005a) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6):1200–1208. https://doi.org/10.1200/JCO.2005.08.003

Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP (2005b) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6):1200–1208. https://doi.org/10.1200/JCO.2005.08.003

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2019) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens, Langversion 1.0, 2019, AWMF-Registernummer: 043/049OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/hodentumoren. Zugegriffen: 07.10.2020

Loriot Y, Texier M, Culine S, Flechon A, Nguyen T, Gravis G, Fizazi K et al (2020) The SEMITEP trial: De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET. J Clin Oncol 38(6_suppl):387. https://doi.org/10.1200/JCO.2020.38.6_suppl.387

Mortensen MS, Bandak M, Kier MGG, Lauritsen J, Agerbaek M, Holm NV, Daugaard G et al (2017) Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer 123(7):1212–1218. https://doi.org/10.1002/cncr.30458

O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14(1):91–96. https://doi.org/10.1093/annonc/mdg020

Oliver RTD, Mead GM, Rustin GJS, Joffe JK, Aass N, Coleman R, Stenning SP et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962. https://doi.org/10.1200/JCO.2009.26.4655

Papachristofilou A, Bedke J, Hayoz S, Fischer N, Schiel X, Schratzenstaller U, Cathomas R et al (2020) Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma. J Clin Oncol 38(6_suppl):405. https://doi.org/10.1200/JCO.2020.38.6_suppl.405

Shamash J, Syed R, Sarker SJ, Sarwar N, Sharma A, Mutsvangwa K, Rustin GJ et al (2019) A phase II study of carboplatin AUC-10 guided by positron emission tomography–defined metabolic response in metastatic seminoma. Eur J Cancer. https://doi.org/10.1016/j.ejca.2019.04.013

Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Cathomas R et al (2011) Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 187(3):158–166. https://doi.org/10.1007/s00066-010-2227-x

SWENOTECA, Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 27(7):1299–1304. https://doi.org/10.1093/annonc/mdw164

Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J, Stotz M et al (2017) Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol 19(11):1400–1408. https://doi.org/10.1007/s12094-017-1742-y

Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Gilbert ES et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. JNCIJ 97(18):1354–1365. https://doi.org/10.1093/jnci/dji278

Utz D, Müller A‑C (2019) Risiko von Zweitmalignomen nach platinbasierter Chemotherapie von Hodentumoren. Strahlenther Onkol 195(2):190–191. https://doi.org/10.1007/s00066-018-1410-3

van de Wetering RAW, Sleijfer S, Feldman DR, Funt SA, Bosl GJ, de Wit R (2018) Controversies in the management of clinical stage I seminoma: carboplatin a decade in-time to start backing out. J Clin Oncol 36(9):837–840. https://doi.org/10.1200/JCO.2017.76.5610

Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ (2012) Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys 83(4):e445–e452. https://doi.org/10.1016/j.ijrobp.2012.01.044

Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A (2017) Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance‑A systematic review. Urol Oncol. https://doi.org/10.1016/j.urolonc.2017.06.047